Last reviewed · How we verify

NCT06031194

Pharmacogenomics Effects on High-Dose Methotrexate Clearance in Patients With Diffuse Large B-Cell Lymphoma

Completed Last updated 6 January 2026
What this trial tests

trial testing Non-Interventional Study in Central Nervous System Lymphoma in 20 participants. Completed in 23 December 2025.

Timeline
10 May 2023
Primary endpoint
5 November 2025
23 December 2025

Quick facts

Lead sponsorOhio State University Comprehensive Cancer Center
StatusCompleted
Study typeOBSERVATIONAL
Enrollment20
Start date10 May 2023
Primary completion5 November 2025
Estimated completion23 December 2025
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Ohio State University Comprehensive Cancer Center

Who can join

18 and older, any sex, with Central Nervous System Lymphoma or Diffuse Large B-Cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study evaluates pharmacogenomic effects on high-dose methotrexate clearance in patients with diffuse large B-cell lymphoma.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Non-Interventional Study

Trials testing the same drug.

Other recruiting trials for Central Nervous System Lymphoma

Currently open trials in the same condition.

Other Ohio State University Comprehensive Cancer Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06031194.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing